Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study

John Lally; Olesya Ajnakina; Nidhita Singh; Poonam Gardner-Sood; Brendon Stubbs; Dominic Stringer; Marta Di Forti; Anthony S. David; Shubulade Smith; Robin M. Murray; Oliver D. Howes; Fiona Gaughran

doi:10.1016/j.schres.2018.08.011

Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study

John Lally, Olesya Ajnakina, Nidhita Singh, Poonam Gardner-Sood, Brendon Stubbs, Dominic Stringer, Marta Di Forti, Anthony S. David, Shubulade Smith, Robin M. Murray, Oliver D. Howes, Fiona Gaughran

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

354 Downloads (Pure)

Abstract

BACKGROUND: There is a paucity of longitudinal research investigating vitamin D in people with early psychosis.

METHOD: Vitamin D levels were measured in 168 patients (64% (n = 108) male, mean age 29.3 (9.8) years) with first episode psychosis (FEP), along with measures of clinical state at baseline and at 12 months follow up. We assessed the a) cross sectional, and; b) longitudinal relationships between continuous and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact for psychosis and at 12 months.

RESULTS: In FEP, 80% (n = 134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at baseline were not cross-sectionally associated with clinical symptoms. Higher vitamin D levels at baseline (n = 77) were significantly associated with better visual reproduction-immediate recall (β = 0.249, 95%CI = -0.012-0.871, p = 0.044). Higher baseline vitamin D levels were prospectively associated with lower total PANSS (β = -0.24, 95%CI = -0.47-0.01, p = 0.04) and PANSS negative symptom scores (β = -0.12, 95%CI = -0.23-0.01, p = 0.04) at 12 months.

CONCLUSION: We identified a prospective association between higher baseline serum Vitamin D levels and lower total psychotic symptoms and negative symptoms of psychosis at 12 months after first contact for psychosis. The results of this study require replication in larger prospective studies, and highlight the need for large randomised trials to assess the effect of vitamin D supplementation on symptoms of psychosis in FEP.

Original language	English
Pages (from-to)	381-388
Number of pages	8
Journal	Schizophrenia Research
Volume	204
Early online date	25 Aug 2018
DOIs	https://doi.org/10.1016/j.schres.2018.08.011
Publication status	Published - Feb 2019

Keywords

25-hydroxyvitamin D (25(OH)D)
Cognitive
FEP
Longitudinal
Negative symptoms
Psychosis
Schizophrenia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2018.08.011

Vitamin D and clinical_Accepted11August2018_GREEN AAM (CC BY-NC-ND)Accepted author manuscript, 259 KBLicence: CC BY-NC-ND

Cite this

@article{11314c1b320f4c5eab66d0d143b4c6a0,

title = "Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study",

abstract = "BACKGROUND: There is a paucity of longitudinal research investigating vitamin D in people with early psychosis.METHOD: Vitamin D levels were measured in 168 patients (64% (n = 108) male, mean age 29.3 (9.8) years) with first episode psychosis (FEP), along with measures of clinical state at baseline and at 12 months follow up. We assessed the a) cross sectional, and; b) longitudinal relationships between continuous and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact for psychosis and at 12 months.RESULTS: In FEP, 80% (n = 134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at baseline were not cross-sectionally associated with clinical symptoms. Higher vitamin D levels at baseline (n = 77) were significantly associated with better visual reproduction-immediate recall (β = 0.249, 95%CI = -0.012-0.871, p = 0.044). Higher baseline vitamin D levels were prospectively associated with lower total PANSS (β = -0.24, 95%CI = -0.47-0.01, p = 0.04) and PANSS negative symptom scores (β = -0.12, 95%CI = -0.23-0.01, p = 0.04) at 12 months.CONCLUSION: We identified a prospective association between higher baseline serum Vitamin D levels and lower total psychotic symptoms and negative symptoms of psychosis at 12 months after first contact for psychosis. The results of this study require replication in larger prospective studies, and highlight the need for large randomised trials to assess the effect of vitamin D supplementation on symptoms of psychosis in FEP.",

keywords = "25-hydroxyvitamin D (25(OH)D), Cognitive, FEP, Longitudinal, Negative symptoms, Psychosis, Schizophrenia",

author = "John Lally and Olesya Ajnakina and Nidhita Singh and Poonam Gardner-Sood and Brendon Stubbs and Dominic Stringer and {Di Forti}, Marta and David, {Anthony S.} and Shubulade Smith and Murray, {Robin M.} and Howes, {Oliver D.} and Fiona Gaughran",

year = "2019",

month = feb,

doi = "10.1016/j.schres.2018.08.011",

language = "English",

volume = "204",

pages = "381--388",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

}

TY - JOUR

T1 - Vitamin D and clinical symptoms in First Episode Psychosis (FEP)

T2 - a prospective cohort study

AU - Lally, John

AU - Ajnakina, Olesya

AU - Singh, Nidhita

AU - Gardner-Sood, Poonam

AU - Stubbs, Brendon

AU - Stringer, Dominic

AU - Di Forti, Marta

AU - David, Anthony S.

AU - Smith, Shubulade

AU - Murray, Robin M.

AU - Howes, Oliver D.

AU - Gaughran, Fiona

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: There is a paucity of longitudinal research investigating vitamin D in people with early psychosis.METHOD: Vitamin D levels were measured in 168 patients (64% (n = 108) male, mean age 29.3 (9.8) years) with first episode psychosis (FEP), along with measures of clinical state at baseline and at 12 months follow up. We assessed the a) cross sectional, and; b) longitudinal relationships between continuous and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact for psychosis and at 12 months.RESULTS: In FEP, 80% (n = 134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at baseline were not cross-sectionally associated with clinical symptoms. Higher vitamin D levels at baseline (n = 77) were significantly associated with better visual reproduction-immediate recall (β = 0.249, 95%CI = -0.012-0.871, p = 0.044). Higher baseline vitamin D levels were prospectively associated with lower total PANSS (β = -0.24, 95%CI = -0.47-0.01, p = 0.04) and PANSS negative symptom scores (β = -0.12, 95%CI = -0.23-0.01, p = 0.04) at 12 months.CONCLUSION: We identified a prospective association between higher baseline serum Vitamin D levels and lower total psychotic symptoms and negative symptoms of psychosis at 12 months after first contact for psychosis. The results of this study require replication in larger prospective studies, and highlight the need for large randomised trials to assess the effect of vitamin D supplementation on symptoms of psychosis in FEP.

AB - BACKGROUND: There is a paucity of longitudinal research investigating vitamin D in people with early psychosis.METHOD: Vitamin D levels were measured in 168 patients (64% (n = 108) male, mean age 29.3 (9.8) years) with first episode psychosis (FEP), along with measures of clinical state at baseline and at 12 months follow up. We assessed the a) cross sectional, and; b) longitudinal relationships between continuous and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact for psychosis and at 12 months.RESULTS: In FEP, 80% (n = 134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at baseline were not cross-sectionally associated with clinical symptoms. Higher vitamin D levels at baseline (n = 77) were significantly associated with better visual reproduction-immediate recall (β = 0.249, 95%CI = -0.012-0.871, p = 0.044). Higher baseline vitamin D levels were prospectively associated with lower total PANSS (β = -0.24, 95%CI = -0.47-0.01, p = 0.04) and PANSS negative symptom scores (β = -0.12, 95%CI = -0.23-0.01, p = 0.04) at 12 months.CONCLUSION: We identified a prospective association between higher baseline serum Vitamin D levels and lower total psychotic symptoms and negative symptoms of psychosis at 12 months after first contact for psychosis. The results of this study require replication in larger prospective studies, and highlight the need for large randomised trials to assess the effect of vitamin D supplementation on symptoms of psychosis in FEP.

KW - 25-hydroxyvitamin D (25(OH)D)

KW - Cognitive

KW - FEP

KW - Longitudinal

KW - Negative symptoms

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85054358505&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2018.08.011

DO - 10.1016/j.schres.2018.08.011

M3 - Article

C2 - 30154029

AN - SCOPUS:85054358505

SN - 0920-9964

VL - 204

SP - 381

EP - 388

JO - Schizophrenia Research

JF - Schizophrenia Research

ER -

Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this